应用复方异丙托溴铵联合布地奈德治疗婴幼儿喘息性疾病的临床疗效分析  

Clinical Efficacy Analysis of Compound Ipratropium Bromide Combined with Budesonide in the Treatment of Infantile Asthmatic Diseases

作　　者：杨丽娟 YANG Lijuan(Department of Pediatrics,First Hospital of Sanming City,Sanming,Fujian Province,365000 China)

机构地区：[1]福建省三明市第一医院儿科,福建三明365000

出　　处：《中外医疗》2022年第14期32-36,共5页China & Foreign Medical Treatment

摘　　要：目的探讨婴幼儿喘息性疾病应用布地奈德+复方异丙托溴铵的临床疗效及应用价值。方法随机选择2020年3月—2021年3月该院收治的100例婴幼儿喘息性疾病患儿为研究对象,参考“随机数表法”分为对照组(n=50例)和观察组(n=50例),对照组实施布地奈德雾化吸入治疗,观察组合用复方异丙托溴铵与布地奈德雾化吸入。比较两组结果:临床总疗效、症状改善时间、肺功能指标、血清指标、不良反应率。结果较对照组研究结果,观察组治疗总有效率明显高(96.00%vs 82.00%),差异有统计学意义(χ^(2)=5.005,P<0.05);同时观察组喘息、喘鸣、咳嗽症状消失时间、住院时间更短,肺功能指标FVC、FEV1、PEF水平更优,hs-CRP、PCT水平更低,差异有统计学意义(P<0.05)。两组患儿不良反应率差异无统计学意义(P>0.05)。结论婴幼儿喘息性疾病治疗中,在布地奈德治疗基础上合用复方异丙托溴铵,可增强临床整体疗效,促进患儿症状改善,加快疾病康复速率,同时可减轻机体炎症反应,改善患儿肺功能。Objective To explore the clinical efficacy and application value of budesonide+compound ipratropium bromide in infants and young children with asthma.Methods Randomly selected 100 infants and young children with wheezing disease who were treated in this hospital from March 2020 to March 2021 as the research objects,and were divided into the control group(n=50 cases)and the observation group(n=50 cases)with reference to the"random number table method",the control group received budesonide inhalation therapy,and the observation group was combined with compound ipratropium bromide and budesonide inhalation.The results of the two groups were compared:total clinical efficacy,symptom improvement time,pulmonary function indexes,serum indexes,and adverse reaction rate.Results Compared with the research results of the control group,the total effective rate of the observation group was significantly higher(96.00%vs 82.00%),and the difference was statistically significant(χ^(2)=5.005,P<0.05).In the observation group,the symptoms of wheezing,wheezing and cough disappeared for shorter time,and the hospital stay was shorter.The levels of FVC,FEV1 and PEF were better,and the levels of HS-CRP and PCT were lower,the differences were statistically significant(P<0.05).There was no statistically significant difference in the adverse reaction rate between the two groups(P>0.05).Conclusion In the treatment of asthmatic diseases in infants and young children,the combined use of compound ipratropium bromide on the basis of budesonide treatment can enhance the overall clinical efficacy,promote the improvement of children's symptoms,and speed up the rate of disease recovery.At the same time,it can reduce the inflammatory response of the body and improve the lung function of children.

关 键 词：婴幼儿 喘息性疾病 复方异丙托溴铵 布地奈德 临床疗效 

分 类 号：R4[医药卫生—临床医学]